About 64x Bio
64x Bio is a Healthcare company based in San Francisco (United States) founded in 2017 by David Thompson, Pamela Silver, Jeff Way, and George M Church. Cell and gene therapies for multiple diseases are developed. 64x Bio has raised $59.65 million across 3 funding rounds from investors including Lifeforce Capital, Northpond Ventures and Michael Chambers. The company has 18 employees. 64x Bio offers products and services including End-to-End Platform. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include Senti Biosciences, Poseida Therapeutics and ADARx Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
64x Bio was founded in 2017 in San Francisco, United States, within the biotechnology sector. Focus is placed on cell and gene therapy development for various disease treatments. A VectorSelect platform is utilized, incorporating DNA library synthesis, next-generation sequencing, and machine learning to design cells for biomanufacturing and therapeutic uses. Genome manipulation is employed to reprogram and edit DNA in organisms.
- Headquarters San Francisco, United States
- Employees 18
- Founders David Thompson, Pamela Silver, Jeff Way, George M Church
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website 64xbio.com
- Social LinkedIn X Facebook Instagram
- Total Equity Funding$59.65M (USD)
in 3 rounds
- Latest Funding Round$55M (USD), Series A
Jan 2022
- InvestorsLifeforce Capital
& 12 more
- Employee Count18
Products & Services of 64x Bio
64x Bio offers a comprehensive portfolio of products and services, including End-to-End Platform.
Platform for designing scalable therapeutic systems efficiently.
Funding Insights of 64x Bio
64x Bio has successfully raised a total of $59.65M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $55 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $59.65M
- Total Rounds 3
- Last Round Series A — $55M
- First Round $150,000
(Jun 2018)
- Investors Count 13
All 3 funding rounds of 64x Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $55M | Series A | – | Lifeforce Capital | |
| Nov 2020 | $4.5M | Seed | – | Refactor Capital, First Round Capital | – |
| Jun 2018 | $150,000 | Seed | – | Y Combinator | – |
13 investors in total: 11 institutional and 2 angel.
Investors in 64x Bio
64x Bio has secured backing from 13 investors, including venture fund and angel investors. Prominent investors backing the company include Lifeforce Capital, Northpond Ventures and Michael Chambers.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on healthcare startups | lifeforcecap.com | San Francisco, United States | ||
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
Future Ventures is focused on early-stage venture capital investments. | future.ventures | Los Altos, United States | ||
US focused seed and early-stage VC firm | firstround.com | San Francisco, United States | ||
Venture capital firm focused on multiple sectors | fiftyyears.com | San Francisco, United States | ||
Early-stage investments are provided to transformative technology companies. | svangel.com | San Francisco, United States | ||
Early stage life science startups are supported by investments. | alix.vc | |||
Investing in early-stage tech companies and ideas. | boxgroup.com | |||
Seed and early-stage investments are made across US and India. | refactor.com | Burlingame, United States | ||
Investor details for 64x Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of 64x Bio
15 people are tracked at 64x Bio (7 in leadership, 6 in board & advisors, 2 in team); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
David Thompson | Co-Founder | Leadership |
Pamela Silver | Co-Founder | Leadership |
Jeff Way | Co-Founder | Leadership |
George M Church | Co-Founder | Leadership |
Lex Rovner | CEO & Co-Founder | Leadership |
Ha Kwan | VP, People | Leadership |
Michele Giovenelli | CFO | Leadership |
Stephen Sofen | Advisor | Board & advisors |
Pam Silver | Co-Founder | Board & advisors |
David Wurtman | Advisor | Board & advisors |
Sander Duncan | Director | Board & advisors |
George Church | Co-Founder | Board & advisors |
Mathew Pletcher | Advisor | Board & advisors |
Kathy Nunez | Operations Manager | Team |
Stephen Martin | Senior Research Associate/lab Owner | Team |
Complete people profiles for 64x Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of 64x Bio
3 dated milestones of 64x Bio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded 64x Bio is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Series A, of $55.0M.
Competitors of 64x Bio
64x Bio has 3 listed competitors in our database, 3 of them funded. They include Senti Biosciences, Poseida Therapeutics and ADARx Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sentibio.com | 2016 | San Francisco, United States | $158M | Cell-based therapies for cancer treatment are developed. | ||
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| adarx.com | 2019 | San Diego, United States | $352.5M | 44 | Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts |
Detailed competitors of 64x Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of 64x Bio
The website of 64x Bio (64xbio.com) receives about 3K visits a month and ranks #6,775,894 among all websites worldwide, #6,766 in Biotechnology and Pharmaceuticals.
- Monthly visits3K
▲ 40.3% vs previous month
- Unique visitors1.1K
per month
- Global rank#6,775,894
among all websites
- Category rank#6,766
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.1
- Average visit41 sec
- DevicesDesktop 55% · Mobile 45%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as 64x Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about 64x Bio
64x Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
64x Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
64x Bio is a funded company, having raised a total of $59.65M across 3 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on Jun 2018.
64x Bio has 18 employees.
64x Bio was founded in 2017 in San Francisco, United States, within the biotechnology sector. Focus is placed on cell and gene therapy development for various disease treatments. A VectorSelect platform is utilized, incorporating DNA library synthesis, next-generation sequencing, and machine learning to design cells for biomanufacturing and therapeutic uses. Genome manipulation is employed to reprogram and edit DNA in organisms.
64x Bio's top competitors include Senti Biosciences, Poseida Therapeutics and ADARx Pharmaceuticals.
64x Bio offers End-to-End Platform.
64x Bio has 13 investors. Key investors include Lifeforce Capital, Northpond Ventures, Michael Chambers, Future Ventures, and First Round Capital.